drugset
drugset / Trial / NCT05921916

Study to Assess the Safety and Tolerability of MBF-118 in Healthy Volunteers

NCT05921916 ↗

Phase 1 Completed 56 enrolled Medibiofarma S.L.
RandomizedSequentialDouble-blindTreatment

Summary

This is a single center, randomised, double blind, placebo controlled clinical study to assess the safety and tolerability of MBF-118 in healthy volunteers.This clinical phase I trial is divided in two stages and involves, first, a single ascending dose (SAD) study in healthy young male volunteers and then a multiple ascending dose (MAD) study in healthy young men and woman. MBF-118 is developed for the treatment of cancer.

Timeline

Start
2020-07-03
Primary completion
2022-09-06
Completion
2022-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject MBF-118 Unknown 100 mg Oral
Subject MBF-118 Unknown 200 mg Oral
Subject MBF-118 Unknown 400 mg Oral
Subject MBF-118 Unknown 600 mg Oral

Indications

cancer